Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.81B 2.84B | Sales 2025 * | 23.61B 3.39B | Capitalization | 118B 16.89B |
---|---|---|---|---|---|
Net income 2024 * | 4.67B 670M | Net income 2025 * | 6.54B 938M | EV / Sales 2024 * | 4.63 x |
Net cash position 2024 * | 25.89B 3.71B | Net cash position 2025 * | 32.22B 4.62B | EV / Sales 2025 * | 3.62 x |
P/E ratio 2024 * |
27
x | P/E ratio 2025 * |
19.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B | |
+106.26% | 10.31B |